{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:45:43Z","timestamp":1784205943185,"version":"3.55.0"},"reference-count":64,"publisher":"Frontiers Media SA","funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["G0802796, MR\/J006394\/1"],"award-info":[{"award-number":["G0802796, MR\/J006394\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"DOI":"10.3389\/fendo.2016.00101","type":"journal-article","created":{"date-parts":[[2016,8,5]],"date-time":"2016-08-05T03:03:00Z","timestamp":1470366180000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":39,"title":["ACTH Antagonists"],"prefix":"10.3389","volume":"7","author":[{"given":"Adrian John","family":"Clark","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Forfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mashal","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Jerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ed","family":"McIver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2016,8,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/0002-9343(76)90908-6","article-title":"Beta-adrenoreceptor blockade in hypertension","volume":"60","author":"Lorimer","year":"1976","journal-title":"Am J Med"},{"key":"B2","first-page":"141","article-title":"H2 receptor antagonists","volume":"35","author":"Siepler","year":"1978","journal-title":"Am J Hosp Pharm"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJM199811263392207","article-title":"Tamoxifen in the treatment of breast cancer","volume":"339","author":"Osborne","year":"1998","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ijcard.2015.02.096","article-title":"Mineralocorticoid receptor antagonists, a class beyond spironolactone \u2013 focus on the special pharmacologic properties of eplerenone","volume":"200","author":"Seferovic","year":"2015","journal-title":"Int J Cardiol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2174\/0929867003375371","article-title":"Androgen receptor antagonists (antiandrogens): structure-activity relationships","volume":"7","author":"Singh","year":"2000","journal-title":"Curr Med Chem"},{"key":"B6","doi-asserted-by":"publisher","first-page":"T141","DOI":"10.1530\/JOE-15-0109","article-title":"60 years of neuroendocrinology: acromegaly","volume":"226","author":"Capatina","year":"2015","journal-title":"J Endocrinol"},{"issue":"98","key":"B7","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1210\/jc.2012-4082","article-title":"Clinical review: the use of vaptans in clinical endocrinology","volume":"2013","author":"Peri","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"B8","doi-asserted-by":"publisher","first-page":"T27","DOI":"10.1530\/JME-15-0268","article-title":"60 years of POMC: the proopiomelanocortin gene: discovery, deletion and disease","volume":"56","author":"Clark","year":"2016","journal-title":"J Mol Endocrinol"},{"issue":"4","key":"B9","doi-asserted-by":"publisher","first-page":"T49","DOI":"10.1530\/JME-15-0261","article-title":"60 years of POMC: from the prohormone theory to proopiomelanocortin and to proprotein convertases (PCSK1 to PCSK9)","volume":"56","author":"Chretien","year":"2016","journal-title":"J Mol Endocrinol"},{"issue":"4","key":"B10","doi-asserted-by":"publisher","first-page":"T1","DOI":"10.1530\/JME-15-0260","article-title":"60 years of POMC: purification and biological characterisation of melanotrophins and corticotrophins","volume":"56","author":"Lowry","year":"2016","journal-title":"J Mol Endocrinol"},{"key":"B11","article-title":"Normal physiology of ACTH and GH release in the hypothalamus and anterior pituitary in man","volume-title":"Endotext [Internet]","author":"Lim","year":"2014"},{"key":"B12","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/BF02918598","article-title":"Corticotropin in human plasma. General considerations","volume":"3","author":"Sch\u00f6nesh\u00f6fer","year":"1984","journal-title":"Surv Immunol Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3389\/fendo.2013.00009","article-title":"The melanocortin receptors and their accessory proteins","volume":"4","author":"Ramachandrappa","year":"2013","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.mce.2010.02.032","article-title":"Identification of domains responsible for specific membrane transport and ligand specificity of the ACTH receptor (MC2R)","volume":"321","author":"Fridmanis","year":"2010","journal-title":"Mol Cell Endocrinol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ygcen.2011.04.006","article-title":"Observations on the ligand selectivity of the melanocortin 2 receptor","volume":"172","author":"Veo","year":"2011","journal-title":"Gen Comp Endocrinol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1677\/joe.1.06019","article-title":"11beta-hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action","volume":"186","author":"Draper","year":"2005","journal-title":"J Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1002\/cphy.c140065","article-title":"Hypothalamic-pituitary \u2013 adrenal axis-feedback control","volume":"5","author":"Keller-Wood","year":"2015","journal-title":"Compr Physiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1210\/jc.2007-2734","article-title":"Treatment of adrenocorticotropin-dependent Cushing\u2019s syndrome: a consensus statement","volume":"93","author":"Biller","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B19","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/j.1365-2265.1981.tb00638.x","article-title":"Prolonged remission in florid Cushing\u2019s syndrome following metyrapone treatment","volume":"14","author":"Beardwell","year":"1981","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1111\/j.1365-2265.1987.tb01174.x","article-title":"Response of pituitary-adrenal axis to corticotrophin releasing hormone in patients with Cushing\u2019s disease before and after ketoconazole treatment","volume":"27","author":"Boscaro","year":"1987","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1056\/NEJM198709243171307","article-title":"The use of ketoconazole as an inhibitor of steroid production","volume":"317","author":"Sonino","year":"1987","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1056\/NEJMoa1105743","article-title":"A 12-month phase 3 study of pasireotide in Cushing\u2019s disease","volume":"366","author":"Colao","year":"2012","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/j.1365-2265.1991.tb03517.x","article-title":"Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing\u2019s syndrome","volume":"35","author":"Verhelst","year":"1991","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1055\/s-0032-1330009","article-title":"The therapy of Cushing\u2019s disease in adults and children: an update","volume":"45","author":"Juszczak","year":"2013","journal-title":"Horm Metab Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1210\/jc.78.2.241","article-title":"Clinical review 54: genetics, diagnosis, and management of 21-hydroxylase deficiency","volume":"78","author":"Miller","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"B26","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.ecl.2009.08.001","article-title":"Steroid 21 hydroxylase deficiency congenital adrenal hyperplasia","volume":"38","author":"Nimkarn","year":"2009","journal-title":"Endocrinol Metab Clin North Am"},{"key":"B27","doi-asserted-by":"publisher","first-page":"4048","DOI":"10.1210\/jc.2002-020611","article-title":"Consensus statement on 21-hydroxylase deficiency from the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology","volume":"87","author":"Joint LWPES\/ESPE CAH Working Group","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"B28","doi-asserted-by":"publisher","first-page":"E1547","DOI":"10.1210\/jc.2014-1486","article-title":"Relationship between final height and health outcomes in adults with congenital adrenal hyperplasia: United Kingdom congenital adrenal hyperplasia adult study executive (CaHASE)","volume":"99","author":"Han","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B29","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","volume":"16","author":"Ryan","year":"2015","journal-title":"Lancet Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1210\/jc.2011-2189","article-title":"Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer","volume":"97","author":"Attard","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B31","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s11102-007-0079-x","article-title":"Dynamic testing in Cushing\u2019s syndrome","volume":"11","author":"Kola","year":"2008","journal-title":"Pituitary"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1126\/science.1325670","article-title":"The cloning of a family of genes that encode the melanocortin receptors","volume":"257","author":"Mountjoy","year":"1992","journal-title":"Science"},{"key":"B33","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1677\/joe.0.1740017","article-title":"Failed export of the adrenocorticotrophin receptor from the endoplasmic reticulum in non-adrenal cells: evidence in support of a requirement for a specific adrenal accessory factor","volume":"174","author":"Noon","year":"2002","journal-title":"J Endocrinol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/ng1501","article-title":"Mutations in MRAP, encoding a new interacting partner of the ACTH receptor, cause familial glucocorticoid deficiency type 2","volume":"37","author":"Metherell","year":"2005","journal-title":"Nat Genet"},{"key":"B35","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1210\/me.2009-0283","article-title":"Minireview: the melanocortin 2 receptor accessory proteins","volume":"24","author":"Webb","year":"2010","journal-title":"Mol Endocrinol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"20244","DOI":"10.1073\/pnas.0708916105","article-title":"Melanocortin-2 receptor accessory protein MRAP forms antiparallel homodimers","volume":"104","author":"Sebag","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1210\/en.2007-1463","article-title":"The melanocortin 2 receptor accessory protein exists as a homodimer and is essential for the function of the melanocortin 2 receptor in the mouse y1 cell line","volume":"149","author":"Cooray","year":"2008","journal-title":"Endocrinology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1210\/en.2010-1053","article-title":"Bioluminescence resonance energy transfer reveals the adrenocorticotropin (ACTH)-induced conformational change of the activated ACTH receptor complex in living cells","volume":"152","author":"Cooray","year":"2011","journal-title":"Endocrinology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1146\/annurev.bi.33.070164.001355","article-title":"Chemistry and metabolic action of nonsteroid hormones","volume":"33","author":"Schwyzer","year":"1964","journal-title":"Ann Rev Biochem"},{"key":"B40","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1749-6632.1977.tb41843.x","article-title":"ACTH: a short introductory review","volume":"297","author":"Schwyzer","year":"1977","journal-title":"Ann N Y Acad Sci"},{"key":"B41","doi-asserted-by":"publisher","first-page":"11329","DOI":"10.1021\/bi0501840","article-title":"Interactions of human melanocortin 4 receptor with nonpeptide and peptide agonists","volume":"44","author":"Pogozheva","year":"2005","journal-title":"Biochemistry"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1021\/bi3013593","article-title":"Molecular characterization of human melanocortin-5 receptor ligand-receptor interaction","volume":"52","author":"Yang","year":"2013","journal-title":"Biochemistry"},{"key":"B43","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1146\/annurev.bi.31.070162.001241","article-title":"Chemistry and function of polypeptide hormones","volume":"31","author":"Hofmann","year":"1962","journal-title":"Annu Rev Biochem"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1002\/hlca.19750580604","article-title":"Hormone-receptor interactions. Demonstration of two message sequences (active sites) in alpha-melanotropin","volume":"58","author":"Eberle","year":"1975","journal-title":"Helv Chim Acta"},{"key":"B45","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1210\/jc.2012-3199","article-title":"Bioinactive ACTH causing glucocorticoid deficiency","volume":"98","author":"Samuels","year":"2013","journal-title":"Clin Endocrinol Metab"},{"key":"B46","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1098\/rspb.1980.0115","article-title":"Structure and function in neuropeptides","volume":"210","author":"Schwyzer","year":"1980","journal-title":"Proc R Soc Lond B Biol Sci"},{"key":"B47","doi-asserted-by":"publisher","first-page":"4948","DOI":"10.1210\/jc.2008-1744","article-title":"The majority of adrenocorticotropin receptor (melanocortin 2 receptor) mutations found in familial glucocorticoid deficiency type 1 lead to defective trafficking of the receptor to the cell surface","volume":"93","author":"Chung","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B48","doi-asserted-by":"publisher","first-page":"27972","DOI":"10.1074\/jbc.M115.668491","article-title":"Adrenocorticotropic hormone (ACTH) responses require actions of the melanocortin-2 receptor accessory protein on the extracellular surface of the plasma membrane","volume":"290","author":"Malik","year":"2015","journal-title":"J Biol Chem"},{"key":"B49","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/0014-5793(71)80521-5","article-title":"Isolated adrenal cells: ACTH(11-24), a competitive antagonist of ACTH(1-39) and ACTH(1-10)","volume":"19","author":"Seelig","year":"1971","journal-title":"FEBS Lett"},{"key":"B50","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/0003-9861(73)90053-2","article-title":"Isolated adrenal cortex cells: ACTH agonists, partial agonists, antagonists; cyclic AMP and corticosterone production","volume":"154","author":"Seelig","year":"1973","journal-title":"Arch Biochem Biophys"},{"key":"B51","doi-asserted-by":"publisher","first-page":"4306","DOI":"10.1073\/pnas.75.9.4306","article-title":"Isolation, characterization, and synthesis of a corticotropin-inhibiting peptide from human pituitary glands","volume":"75","author":"Li","year":"1978","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B52","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/0022-4731(89)90261-6","article-title":"Effects of ACTH-(11-24) on the corticosteroid production of isolated adrenocortical cells","volume":"32","author":"Szalay","year":"1989","journal-title":"J Steroid Biochem"},{"key":"B53","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/0014-5793(84)81009-1","article-title":"The anomalous effect of some ACTH-fragments missing the amino acid sequence 1-10 on the corticosteroidogenesis in purified isolated rat adrenal cells","volume":"173","author":"Goverde","year":"1984","journal-title":"FEBS Lett"},{"key":"B54","first-page":"29","article-title":"Synthetic peptide KKRR corresponding to the human ACTH fragment 15-18 is an antagonist of the ACTH receptor","volume":"34","author":"Kovalitskaia","year":"2008","journal-title":"Bioorg Khim"},{"key":"B55","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1073\/pnas.71.1.80","article-title":"ACTH antagonists","volume":"71","author":"Hofmann","year":"1974","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B56","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ygcen.2012.11.011","article-title":"Using the human melanocortin-2 receptor as a model for analyzing hormone\/receptor interactions between a mammalian MC2 receptor and ACTH(1-24)","volume":"181","author":"Liang","year":"2013","journal-title":"Gen Comp Endocrinol"},{"key":"B57","volume-title":"ACTH Antagonist Peptides","author":"Dores","year":"2012"},{"key":"B58","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.mce.2014.07.003","article-title":"Development of potent selective competitive-antagonists of the melanocortin type 2 receptor","volume":"394","author":"Bouw","year":"2014","journal-title":"Mol Cell Endocrinol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3389\/fendo.2016.00023","article-title":"Effect of novel melanocortin type 2 receptor antagonists on the corticosterone response to ACTH in the neonatal rat adrenal gland in vivo and in vitro","volume":"7","author":"Nensey","year":"2016","journal-title":"Front Endocrinol (Lausanne)."},{"key":"B60","article-title":"In vivo suppression of corticosterone in rodent models of Cushing\u2019s disease with a selective, peptide MC2 receptor antagonist","volume-title":"Abstract presented to the Endocrine Society Annual Meeting","author":"Halem","year":"2016"},{"key":"B61","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/ijo.2013.80","article-title":"The melanocortin-4 receptor as target for obesity treatment: a systematic review of emerging pharmacological therapeutic options","volume":"38","author":"Fani","year":"2014","journal-title":"Int J Obes (Lond)"},{"key":"B62","article-title":"A novel anti-ACTH antibody (ALD1613) neutralizes ACTH activity and reduced glucocorticoids in rats and nonhuman primates","volume-title":"Abstract presented to the Endocrine Society Annual Meeting","author":"Feldhaus","year":"2016"},{"key":"B63","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1073\/pnas.85.2.592","article-title":"Isolation and structure of corticostatin peptides from rabbit fetal and adult lung","volume":"85","author":"Zhu","year":"1988","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B64","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/ncpendmet0165","article-title":"Mechanisms of disease: the adrenocorticotropin receptor and disease","volume":"2","author":"Clark","year":"2006","journal-title":"Nat Clin Pract Endocrinol Metab"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"deposited":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T00:19:39Z","timestamp":1656980379000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/Article\/10.3389\/fendo.2016.00101\/abstract"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,5]]},"references-count":64,"URL":"https:\/\/doi.org\/10.3389\/fendo.2016.00101","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,5]]}}}